1. Home
  2. AADI vs PMN Comparison

AADI vs PMN Comparison

Compare AADI & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AADI
  • PMN
  • Stock Information
  • Founded
  • AADI 2011
  • PMN 2004
  • Country
  • AADI United States
  • PMN Canada
  • Employees
  • AADI N/A
  • PMN N/A
  • Industry
  • AADI Biotechnology: Pharmaceutical Preparations
  • PMN Pharmaceuticals and Biotechnology
  • Sector
  • AADI Health Care
  • PMN Health Care
  • Exchange
  • AADI Nasdaq
  • PMN Nasdaq
  • Market Cap
  • AADI 33.6M
  • PMN 42.7M
  • IPO Year
  • AADI N/A
  • PMN N/A
  • Fundamental
  • Price
  • AADI $1.57
  • PMN $2.12
  • Analyst Decision
  • AADI Buy
  • PMN Strong Buy
  • Analyst Count
  • AADI 2
  • PMN 1
  • Target Price
  • AADI $5.00
  • PMN $8.00
  • AVG Volume (30 Days)
  • AADI 294.5K
  • PMN 9.1K
  • Earning Date
  • AADI 08-07-2024
  • PMN 08-12-2024
  • Dividend Yield
  • AADI N/A
  • PMN N/A
  • EPS Growth
  • AADI N/A
  • PMN N/A
  • EPS
  • AADI N/A
  • PMN N/A
  • Revenue
  • AADI $23,840,000.00
  • PMN N/A
  • Revenue This Year
  • AADI $4.21
  • PMN N/A
  • Revenue Next Year
  • AADI $8.61
  • PMN N/A
  • P/E Ratio
  • AADI N/A
  • PMN N/A
  • Revenue Growth
  • AADI 26.97
  • PMN N/A
  • 52 Week Low
  • AADI $1.28
  • PMN $0.95
  • 52 Week High
  • AADI $7.24
  • PMN $4.21
  • Technical
  • Relative Strength Index (RSI)
  • AADI 50.71
  • PMN 58.06
  • Support Level
  • AADI $1.46
  • PMN $1.93
  • Resistance Level
  • AADI $1.69
  • PMN $2.20
  • Average True Range (ATR)
  • AADI 0.10
  • PMN 0.18
  • MACD
  • AADI 0.02
  • PMN 0.00
  • Stochastic Oscillator
  • AADI 67.75
  • PMN 70.56

About AADI Aadi Bioscience Inc.

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: